Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 27Unknown 14Completed 14Not yet recruiting 7Terminated 4Active not recruiting 4Withdrawn 3Suspended 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 6Genitourinary 5Breast 3Plasma cell 2Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Myeloid 1Lymphoid 1Gynecologic 1Endocrine 1

Conditions

Breast Neoplasms 2Metastatic HER2-positive Breast Cancer With Brain Metastasis 1

Interventions

Paclitaxel 31Cyclophosphamide 25Trastuzumab 23Doxorubicin 17Docetaxel 15Carboplatin 15pembrolizumab 13Radiotherapy 11Letrozole 11Capecitabine 11exemestane 10Fulvestrant 10Magnetic Resonance Spectroscopy 8Lapatinib 8Biopsy 8eribulin 7abemaciclib 7Taxes 7Bevacizumab 7Anastrozole 7pertuzumab 6palbociclib 6Neoadjuvant Therapy 6Goserelin 6Drug Therapy 6Aromatase Inhibitors 6130-nm albumin-bound paclitaxel 6Therapeutics 5Saline Solution 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Injections × Breast × Clear all
NCT05634954 2025-10-23

Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer

GE Healthcare

Phase 1 Withdrawn
Breast

Breast Neoplasms

NCT03121989 2023-03-30

LABC

Sunnybrook Health Sciences Centre

Phase 1 Withdrawn
Breast

Breast Neoplasms

NCT03203616 2018-11-29

KIARA

Jules Bordet Institute

Phase 2 Withdrawn
Breast

Metastatic HER2-positive Breast Cancer With Brain Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡